Skip to Content

Butoconazole topical Pregnancy and Breastfeeding Warnings

Butoconazole topical is also known as: Femstat 3, Femstat Prefill, Gynazole-1, Mycelex-3

Butoconazole topical Pregnancy Warnings

Animal studies have failed to reveal evidence of teratogenicity; resorption rate increased and litter size decreased in pregnant rats administered 6 mg/kg/day intravaginally during organogenesis (dose represents 130- to 353-fold margin of safety based on serum levels in rats after intravaginal administration compared to serum levels in humans after intravaginal use at recommended therapeutic dose). No adverse effect observed when pregnant rats were administered up to 50 mg/kg/day orally throughout organogenesis (5 times human dose based on mg/m2), but daily oral doses of 100, 300, or 750 mg/kg/day (10, 30, or 75 times human dose based on mg/m2) resulted in fetal malformations (abdominal wall defects, cleft palate) as well as maternal toxicity; no adverse effects on litters were observed in rabbits, even at maternally toxic doses (e.g., 150 mg/kg, 24 times human dose based on mg/m2). This drug caused dystocia in rats, but not rabbits, when administered through parturition. There are no controlled data in human pregnancy; however, use during the second and third trimester has been documented with no adverse fetal outcome. In a review of 229,101 deliveries to Michigan Medicaid patients, 444 first-trimester exposures to this drug and 2450 exposures any time during pregnancy were recorded. A total of 16 birth defects were reported with first trimester exposure (17 expected) and included (observed/expected) 4/4 cardiovascular defects and 1 spina bifida. These data do not support an association between use of this drug and birth defects (written communication, Franz Rosa, MD, Food and Drug Administration, 1994). AU TGA pregnancy category B3: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus. AU TGA pregnancy category: B3 US FDA pregnancy category: C

See references

Butoconazole topical Breastfeeding Warnings

Caution is recommended; according to some experts, other antifungal agents may be preferred, particularly while breastfeeding newborn or preterm infants. Excreted into human milk: Unknown Excreted into animal milk: Yes Comments: -This drug has not been studied during breastfeeding. -The effects in the nursing infant are unknown; about 5.5% of a vaginal dose is absorbed and the plasma half-life is 21 to 24 hours.

See references

References for pregnancy information

  1. TGA. Therapeutic Goods Administration. Australian Drug Evaluation Committee "Prescribing medicines in pregnancy: an Australian categorisation of risk of drug use in pregancy. Available from: URL:" ([1999]):
  2. "Product Information. Femstat (butoconazole)." Syntex Laboratories Inc, Palo Alto, CA.

References for breastfeeding information

  1. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):
  2. "Product Information. Femstat (butoconazole)." Syntex Laboratories Inc, Palo Alto, CA.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.